How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Molybdenum-Technetium Generator Market
- By Generator Type: Molybdenum-99/Technetium-99m Generator, Low Specific Activity (LSA) Molybdenum Generator, High Specific Activity (HSA) Molybdenum Generator
- By Application: Diagnostic Imaging, Therapeutic Procedures, Research and Development
- By End-User: Hospitals, Diagnostic Imaging Centers, Nuclear Medicine Laboratories, Research Institutes
- By Elution Volume: Low Volume Elution Generators, Medium Volume Elution Generators, High Volume Elution Generators
- By Elution Frequency: Daily Elution Generators, Twice Daily Elution Generators, Multiple Times Daily Elution Generators
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Molybdenum-99/Technetium-99m Generator leads By Generator Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 10 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 272 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.172 →
- 12 Company Profiles 10 players: SWOT & benchmarking p.180 →
Full report · locked preview
Everything inside the Molybdenum-Technetium Generator Market report
A complete, evidence-based study - 12 chapters and 114 sections covering market size, segmentation across 5 axes, regional analysis and 10 company profiles, forecast to 2033.
Segmentation covered
Generator Type 3
Application 3
End-User 4
Elution Volume 3
Elution Frequency 3
Companies profiled
Lantheus Medical Imaging
Curium Pharma
Nordion (a Sotera Health company)
GE Healthcare
Mallinckrodt Pharmaceuticals
Bracco Imaging
IBA Molecular
Advanced Accelerator Applications (a Novartis company)
Cyclopharm
NTP Radioisotopes
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
10 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Lantheus Medical Imaging
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Curium Pharma
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Nordion (a Sotera Health company)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →GE Healthcare
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Mallinckrodt Pharmaceuticals
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.178 →Bracco Imaging
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.184 →IBA Molecular
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Advanced Accelerator Applications (a Novartis company)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Cyclopharm
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.202 →NTP Radioisotopes
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.209 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$5,246M by 2033 · 6.5% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Molybdenum-99/Technetium-99m Generator72.8
- Low Specific Activity (LSA) Molybdenum Generator9.2
- High Specific Activity (HSA) Molybdenum Generator18.1
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,046M → $1,693M · 6.2%
Europe$729.0M → $1,328M · 7.8%
Asia Pacific$665.6M → $991.8M · 5.1%
Latin America$412.0M → $672.9M · 6.3%
Middle East and Africa$316.9M → $469.7M · 5.0%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →6.452026
6.472027
6.492028
6.502029
6.492030
6.512031
6.522032
6.532033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Lantheus Medical Imaging11.2
- Curium Pharma26.5
- Nordion (a Sotera Health company)6.0
- GE Healthcare4.9
- Mallinckrodt Pharmaceuticals9.7
- Bracco Imaging13.7
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Generator Type29.4%
Application15.1%
End-User16.5%
Elution Volume27.9%
Elution Frequency11.1%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America32.8
- Europe25.8
- Asia Pacific19.2
- Latin America13.1
- Middle East and Africa9.1
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Lantheus Medical Imaging | 84 | 87 | 97 | 90 | 78 | 81 | 86 |
| Curium Pharma | 74 | 83 | 73 | 80 | 84 | 70 | 77 |
| Nordion (a Sotera Health company) | 68 | 81 | 83 | 63 | 79 | 74 | 75 |
| GE Healthcare | 66 | 78 | 71 | 76 | 79 | 80 | 75 |
| Mallinckrodt Pharmaceuticals | 52 | 73 | 58 | 58 | 68 | 61 | 62 |
| Bracco Imaging | 53 | 55 | 68 | 60 | 71 | 47 | 59 |
| IBA Molecular | 50 | 61 | 65 | 42 | 50 | 45 | 52 |
| Advanced Accelerator Applications (a Novartis company) | 45 | 58 | 57 | 49 | 42 | 53 | 51 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Lantheus Medical Imaging
- Curium Pharma
- Nordion (a Sotera Health company)
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Lantheus Medical Imaging | ✓ | ✓ | ✓ | ✓ | ✓ | ◐ |
| Curium Pharma | ◐ | ✓ | ◐ | ✓ | ✓ | ◐ |
| Nordion (a Sotera Health company) | ◐ | ◐ | ✓ | − | ◐ | ✓ |
| GE Healthcare | ◐ | ✓ | − | ✓ | ◐ | ◐ |
| Mallinckrodt Pharmaceuticals | ◐ | ◐ | ◐ | − | ◐ | − |
| Bracco Imaging | − | ◐ | ◐ | ✓ | ◐ | − |
| IBA Molecular | ◐ | ◐ | − | − | − | − |
| Advanced Accelerator Applications (a Novartis company) | − | − | − | − | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Lantheus Medical Imaging86
2Curium Pharma77
3Nordion (a Sotera Health company)75
4GE Healthcare75
5Mallinckrodt Pharmaceuticals62
6Bracco Imaging59
7IBA Molecular52
8Advanced Accelerator Applications (a Novartis company)51
Competitive tiers
§8.4 · p.172 →Leader1
Set the pace on share, breadth and innovation.
Lantheus Medical Imaging
Challenger3
Strong scale, closing on the leaders.
Curium PharmaNordion (a Sotera Health company)GE Healthcare
Contender2
Focused players with pockets of strength.
Mallinckrodt PharmaceuticalsBracco Imaging
Niche2
Specialists in a single segment or region.
IBA MolecularAdvanced Accelerator Applications (a Novartis company)
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Generator Type in North America, then scale across Molybdenum-Technetium Generator Market — a $334M beachhead inside a $5.72B market.
Beachhead (SOM)$334Mobtainable near-term
Serviceable (SAM)$1.97Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale5 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion92 fit
Molybdenum-99/Technetium-99m Generator
Best fit — highest urgency & budget in Generator Type.
Economic buyer81 fit
Low Specific Activity (LSA) Molybdenum Generator
Strong fit — clear ROI and a fast path to value.
End user70 fit
High Specific Activity (HSA) Molybdenum Generator
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Generator Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Application & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + End-User
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales44%
Partner / channel28%
Digital / self-serve21%
Marketplaces8%
Positioning & messaging
§GTM 2 · p.194 →For Generator Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Molybdenum-Technetium Generator Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified43%
Sales qualified22%
Evaluation14%
Closed-won8%
$13.0KCAC
$52KLTV
4.0:1LTV : CAC
< 2 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Molybdenum-Technetium Generator Market is a resilient opportunity — $5.18B by 2033, compounding at 4.8%.
TAM · 2025$3.57Btoday
TAM · 2033$5.18Bforecast
CAGR4.8%2027–2033
Cumulative$39.0Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$5.18BTotal addressable market
SAM$1.90BServiceable available market
SOM$409MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →4.8% CAGR
Demand compounds through 2033, outpacing GDP across Generator Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Generator Type moving from early to mainstream — durable secular demand.
Consolidation upside
10+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$5.18BLarge & growingTAM by 2033 at 4.8% CAGR
$1.90BServiceable nowreachable with today’s model
$409MBeachhead winobtainable near-term share
10+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$4.04BBear3.1% CAGR
$5.18BBase4.8% CAGR
$6.64BBull6.3% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Application optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Molybdenum-Technetium Generator Market — a $637M market by 2033. Plan: grow share from 8.6% to 18.4%.
Market size · 2033$637Mtotal addressable
Market CAGR5.4%2027–2033
Target share18.4%from 8.6% today
Revenue ambition$117Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 8.6% | 18.4% | At risk |
| Revenue | $53M | $117M | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | At risk |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | On track |
| Gross margin | 28.3% | 44.7% | On track |
| Customer retention | 88.8% | 92.5% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Generator Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Application capability
A defensible second engine — invest in Application to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Generator Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Application
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $17M capacity & capability investment
- Greenlight bolt-on M&A in Application
- Authorise North America expansion plan
- Fund R&D program for Generator Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownBehind
- Competitive share lossAt risk
- Input-cost & supply riskAt risk
- Regulatory / policy changeAt risk
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Molybdenum-Technetium Generator Market conversation — a $4.16B market you can size, segment and defend in minutes.
Market size · 2033$4.16Btotal opportunity
Growth11.0%CAGR to 2033
Addressable buyers1,029+accounts in scope
Typical ROI7.5×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Generator Type
Goal Grow share in Generator Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →7.5×return on cost, year one
< 3 mopayback period
$91K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
10+players profiled in this market
Coverage includes
Lantheus Medical ImagingCurium PharmaNordion (a Sotera Health company)GE HealthcareMallinckrodt PharmaceuticalsBracco ImagingIBA MolecularAdvanced Accelerator Applications (a Novartis company)+2 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Molybdenum-Technetium Generator Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Molybdenum-Technetium Generator Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Molybdenum Cofactor Deficiency Type-A (MoCoD-A) Treatment Market
Market size, share, segmentation and regional forecast.
$4.0B market · 2025 base year
View reportMolybdenum-99 & Technetium-99m Market
Market size, share, segmentation and regional forecast.
$2.5B market · 2025 base year
View reportMolt Mouth Gag Market
Market size, share, segmentation and regional forecast.
$850M market · 2025 base year
View reportMolsidomine Market
Market size, share, segmentation and regional forecast.
$4.6B market · 2025 base year
View reportMolnupiravir Market
Market size, share, segmentation and regional forecast.
$2.3B market · 2025 base year
View reportMolluscum Contagiosum (MC) Treatment Market
Market size, share, segmentation and regional forecast.
$5.1B market · 2025 base year
View reportMolindone Hydrochloride Market
Market size, share, segmentation and regional forecast.
$1.1B market · 2025 base year
View reportMole Removal Pens Market
Market size, share, segmentation and regional forecast.
$2.9B market · 2025 base year
View reportMolecule Biological Research Reagents Market
Market size, share, segmentation and regional forecast.
$2.7B market · 2025 base year
View reportMolecular Weight Marker Market
Market size, share, segmentation and regional forecast.
$2.5B market · 2025 base year
View reportMolecular Transport Medium Market
Market size, share, segmentation and regional forecast.
$4.1B market · 2025 base year
View reportMolecular Theranostics Market
Market size, share, segmentation and regional forecast.
$2.0B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.